<DOC>
	<DOC>NCT02857608</DOC>
	<brief_summary>Prospective, open-label, within-subject, multi-center pilot study of Lymphoseek in the detection of lymph nodes in subjects with known squamous cell carcinoma of the anus.</brief_summary>
	<brief_title>A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the Anus</brief_title>
	<detailed_description>Prospective, open-label, within-subject, multi-center pilot study of Lymphoseek in the detection of lymph nodes in subjects with known squamous cell carcinoma of the anus. All subjects will receive a single dose of 50 Âµg Lymphoseek radiolabeled with 0.5 millicurie (mCi) (18.5 MBq) 99mTc.</detailed_description>
	<mesh_term>Anus Neoplasms</mesh_term>
	<mesh_term>Dextrans</mesh_term>
	<mesh_term>Technetium Tc 99m Pentetate</mesh_term>
	<criteria>Subject has provided written informed consent with Health Insurance Portability and Accountability Act of 1996 (HIPAA) authorization Has histologically confirmed squamous cell carcinoma of the anus (anal canal or perianus) Has a documented clinical stage using the tumor, lymph node, metastasis staging (TNM) classification system that was established by at least physical exam with manual palpation, digital anorectal examination, highresolution anoscopy and PET/CT imaging evaluation of the bilateral inguinal area Is at least 18 years of age at the time of consent Has an Eastern Cooperative Oncology Group (ECOG) performance status of Grade 0 to 3 If of childbearing potential, the subject has a negative pregnancy test within 48 hours before administration of Lymphoseek, has been surgically sterilized, or has been postmenopausal for at least 1 year The subject has had radiation therapy, chemotherapy or immunotherapy within the 30 days prior to Lymphoseek administration Has had previous surgery or node dissection (exclusive of fine needle aspiration) or radiation to node basins that would be involved in the intraoperative lymphatic mapping procedure Has a known allergy to dextran Is breastfeeding or pregnant Before the administration of Lymphoseek, has received any radiopharmaceutical within 7 radioactive halflives of that radiopharmaceutical Has received an investigational product within the 30 days prior to Lymphoseek administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>